急性心肌梗死。
Acute myocardial infarction.
机构信息
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Executive Director Cardiometabolic Trials, Harvard Clinical Research Institute, Boston, MA, USA.
出版信息
Lancet. 2017 Jan 14;389(10065):197-210. doi: 10.1016/S0140-6736(16)30677-8. Epub 2016 Aug 5.
Acute myocardial infarction has traditionally been divided into ST elevation or non-ST elevation myocardial infarction; however, therapies are similar between the two, and the overall management of acute myocardial infarction can be reviewed for simplicity. Acute myocardial infarction remains a leading cause of morbidity and mortality worldwide, despite substantial improvements in prognosis over the past decade. The progress is a result of several major trends, including improvements in risk stratification, more widespread use of an invasive strategy, implementation of care delivery systems prioritising immediate revascularisation through percutaneous coronary intervention (or fibrinolysis), advances in antiplatelet agents and anticoagulants, and greater use of secondary prevention strategies such as statins. This seminar discusses the important topics of the pathophysiology, epidemiological trends, and modern management of acute myocardial infarction, focusing on the recent advances in reperfusion strategies and pharmacological treatment approaches.
急性心肌梗死传统上分为 ST 段抬高型心肌梗死和非 ST 段抬高型心肌梗死;然而,两种类型的治疗方法相似,为简化起见,可以对急性心肌梗死的整体管理进行回顾。尽管在过去十年中预后有了显著改善,但急性心肌梗死仍然是全球发病率和死亡率的主要原因。这一进展是由于几个主要趋势的结果,包括风险分层的改善、更广泛地采用介入策略、通过经皮冠状动脉介入治疗(或溶栓)优先实施即时血运重建的护理提供系统、抗血小板药物和抗凝药物的进步,以及更广泛地使用二级预防策略,如他汀类药物。本研讨会讨论了急性心肌梗死的病理生理学、流行病学趋势和现代管理的重要议题,重点介绍了再灌注策略和药物治疗方法的最新进展。